Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec:110:105466.
doi: 10.1016/j.ebiom.2024.105466. Epub 2024 Nov 29.

The role of neuroinflammation in cerebral amyloid angiopathy

Hilde van den Brink  1 , Sabine Voigt  2 , Mariel Kozberg  3 , Ellis S van Etten  4
Affiliations
Review

The role of neuroinflammation in cerebral amyloid angiopathy

Hilde van den Brink et al. EBioMedicine. 2024 Dec.

Abstract

Cerebral amyloid angiopathy (CAA) is a cerebrovascular disease characterized by vascular amyloid-β (Aβ) deposition. CAA is often seen in the brains of elderly individuals and in a majority of patients with Alzheimer's disease. The molecular pathways triggered by vascular Aβ, causing vessel wall breakdown and ultimately leading to intracerebral haemorrhage and cognitive decline, remain poorly understood. The occurrence of CAA-related inflammation (CAA-ri) and Amyloid-Related Imaging Abnormalities (ARIA) have sparked interest for a role of neuroinflammation in CAA pathogenesis. This review discusses prior studies of neuroinflammation in CAA and outlines potential future research directions targeting candidates such as matrix metalloproteinases, complement activation, microglial activation, reactive astrocytes and parenchymal border macrophages. Understanding the role of neuroinflammation in CAA pathogenesis could help identify new therapeutic strategies.

Keywords: ARIA; Amyloid-β; Cerebral amyloid angiopathy; Cerebral amyloid angiopathy-related inflammation; Neuroinflammation.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests MK has received consulting fees from Kisbee Therapeutics and Hoffman–La Roche, and receives research funding through a sponsored research agreement with Therini Bio. EvE has received reimbursement for travel expenses and accommodation costs for the international CAA conference. She is an unpaid member of the steering committee for a multicenter CAA treatment trial by Alnylam Pharmaceuticals Inc. She is also part of a workgroup on ARIA in collaboration with the American Alzheimer's Association (unpaid). HvdB and SV declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Components of the immune system that have shown interaction with vessels affected by CAA. Aβ, Amyloid-beta; EC, endothelial cell; SMC, smooth muscle cell.
See this image and copyright information in PMC

References

    1. Jäkel L., De Kort A.M., Klijn C.J.M., Schreuder F.H.B.M., Verbeek M.M. Prevalence of cerebral amyloid angiopathy: a systematic review and meta-analysis. Alzheimers Dement. 2022;18(1):10–28. - PMC - PubMed
    1. Greenberg S.M., Bacskai B.J., Hernandez-Guillamon M., Pruzin J., Sperling R., Van Veluw S.J. Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways. Nat Rev Neurol. 2020;16(1):30–42. - PMC - PubMed
    1. van Veluw S.J., Scherlek A.A., Freeze W.M., et al. Different microvascular alterations underlie microbleeds and microinfarcts. Ann Neurol. 2019;86(2):279–292. - PMC - PubMed
    1. Long J.M., Holtzman D.M. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312–339. - PMC - PubMed
    1. Kinnecom C., Lev M.H., Wendell L., et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology. 2007;68(17):1411–1416. - PubMed

MeSH terms

Substances

LinkOut - more resources